<PubmedArticle>
<MedlineCitation Owner="NLM" Status="MEDLINE">
<PMID Version="1">12557141</PMID>
<DateCompleted>
<Year>2003</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2007</Year>
<Month>11</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print">
<Journal>
<ISSN IssnType="Print">0016-5085</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>124</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2003</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Gastroenterology</Title>
<ISOAbbreviation>Gastroenterology</ISOAbbreviation>
</Journal>
<ArticleTitle>Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.</ArticleTitle>
<Pagination>
<MedlinePgn>352-60</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">CCR5Delta32, a 32-base pair deletion of the CC chemokine receptor (CCR) 5 gene, is associated with slowed human immunodeficiency virus disease progression in heterozygotes and protection against infection in homozygotes. A recent study found a higher than expected frequency of CCR5Delta32/Delta32 in patients with hepatitis C virus infection. The roles of other disease-associated chemokine system polymorphisms have not been evaluated in hepatitis C virus infection.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">Six chemokine system polymorphisms (CCR5Delta32, CCR5 promoter 59029-G/A, CCR2 -64I, RANTES [regulated upon activation, normal T cells expressed and secreted] -403 -G/A, and -28 -C/G and stromal derived factor 1 -3'A) were studied in 417 patients with liver diseases (339 with hepatitis C) and 2380 blood donors. The clinical parameters of hepatitis C virus infection were compared between carriers and noncarriers of each genetic variant.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">The frequency of CCR5Delta32 homozygosity was 0.8% in whites with hepatitis C virus and 1.1% in controls (P = 0.75). The CCR5Delta32 allele was not associated with any of the clinical parameters of hepatitis C virus infection. Hepatitis C virus-seropositive whites with the RANTES -403-A allele were less likely to have severe hepatic inflammation compared with those without (odds ratio, 0.34; P = 0.03). In multivariate analysis, the CCR5 promoter 59029 -A allele was marginally associated with a sustained response to interferon therapy (odds ratio, 3.07; P = 0.048).</AbstractText>
<AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this cohort, the frequency of CCR5Delta32 homozygosity in patients with hepatitis C was similar to controls. The high prevalence of CCR5Delta32 homozygosity in the hepatitis C virus patients of the earlier study likely reflects resistance to human immunodeficiency virus infection in hemophiliacs rather than a susceptibility to hepatitis C virus infection. Expression of CCR5 and RANTES may be important in the modulation of hepatic inflammation and response to interferon therapy in chronic hepatitis C.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Promrat</LastName>
<ForeName>Kittichai</ForeName>
<Initials>K</Initials>
<AffiliationInfo>
<Affiliation>The Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. promrat@nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>McDermott</LastName>
<ForeName>David H</ForeName>
<Initials>DH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gonzalez</LastName>
<ForeName>Carlos M</ForeName>
<Initials>CM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Kleiner</LastName>
<ForeName>David E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Koziol</LastName>
<ForeName>Deloris E</ForeName>
<Initials>DE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Lessie</LastName>
<ForeName>Matthew</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Merrell</LastName>
<ForeName>Maya</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Soza</LastName>
<ForeName>Alejandro</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Heller</LastName>
<ForeName>Theo</ForeName>
<Initials>T</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ghany</LastName>
<ForeName>Marc</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Park</LastName>
<ForeName>Yoon</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Alter</LastName>
<ForeName>Harvey J</ForeName>
<Initials>HJ</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Hoofnagle</LastName>
<ForeName>Jay H</ForeName>
<Initials>JH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Murphy</LastName>
<ForeName>Philip M</ForeName>
<Initials>PM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Liang</LastName>
<ForeName>T Jake</ForeName>
<Initials>TJ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Gastroenterology</MedlineTA>
<NlmUniqueID>0374630</NlmUniqueID>
<ISSNLinking>0016-5085</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C515334">CCR2 protein, human</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054390">Receptors, CCR2</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019713">Receptors, CCR5</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019707">Receptors, Chemokine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>9008-11-1</RegistryNumber>
<NameOfSubstance UI="D007372">Interferons</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.6.1.2</RegistryNumber>
<NameOfSubstance UI="D000410">Alanine Transaminase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="ErratumIn">
<RefSource>Gastroenterology. 2003 Apr;124(4):1168.</RefSource>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000410">Alanine Transaminase</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000483">Alleles</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D000998">Antiviral Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018946">Chemokine CCL5</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D018450">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D005787">Gene Frequency</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016174">Hepacivirus</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000302">isolation &amp; purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019698">Hepatitis C, Chronic</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006720">Homozygote</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D007372">Interferons</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008103">Liver Cirrhosis</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000821">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y" UI="D011110">Polymorphism, Genetic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D054390">Receptors, CCR2</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019713">Receptors, CCR5</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019707">Receptors, Chemokine</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="N" UI="D019562">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2003</Year>
<Month>1</Month>
<Day>31</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2003</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2003</Year>
<Month>1</Month>
<Day>31</Day>
<Hour>4</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">12557141</ArticleId>
<ArticleId IdType="doi">10.1053/gast.2003.50061</ArticleId>
<ArticleId IdType="pii">S0016508502159129</ArticleId>
</ArticleIdList>
</PubmedData>
</PubmedArticle>